GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.00+0.08 (+4.17%)
Close on Nov 17, 2026Market cap $90.49MP/E –Yield –
Earnings
Genelux's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Genelux's earnings releases, newest first
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Genelux has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Genelux puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Genelux filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Update
- News
- Results
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
See a number that looks wrong?